Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte

Significance of Kiji Therapeutics

Kiji Therapeutics focuses on addressing the unmet medical needs associated with inflammatory diseases through the use of genetically engineered mesenchymal stromal cells (MSCs). The company aims to professionalize MSC therapy by utilizing induced pluripotent stem cells (iPSCs) to ensure consistency, scalability, and cost-effectiveness in manufacturing. By targeting inflammation through advanced engineering techniques, Kiji aims to produce therapeutic products that effectively modulate the immune system, specifically by secreting high levels of interleukin-10 (IL-10) at sites of inflammation. This strategic approach seeks to enhance the efficacy of MSC therapies beyond current offerings, showing promise in conditions like graft-versus-host disease (GVHD) and inflammatory bowel disease (IBD).